The Food and Drug Administration (FDA) has approved Jatenzo (testosterone undecanoate; Clarus Therapeutics) capsules for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: congenital or acquired primary hypogonadism or hypogonadotropic hypogonadism.
Janssen announced the submission of a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) for Invokana (canagliflozin) to reduce the risk of end-stage renal disease and renal or cardiovascular (CV) death in adults with type 2 diabetes and chronic kidney disease.
Urovant Sciences announced topline data from the phase 3 EMPOWUR trial which evaluated vibegron in adult patients with symptoms of overactive bladder.
Overactive bladder and urinary incontinence dosing regimen chart for anticholinergics, antispasmodic/anticholinergics, muscarinic antagonists, and synthetic vasopressin.
Oral antibiotics for urinary tract infections (UTIs) treatment chart including dosing and duration.
Myocardial infarction following the kidney stone procedure is twice as likely among patients with 3 to 4 components of metabolic syndrome vs no components.
Development of kidney stones is 6.2-fold more likely among patients with persistent hyponatremia than those without a history of hyponatremia.
Percutaneous nephrostomy is associated with better outcomes than retrograde ureteral stent placement in patients with hydronephrosis secondary to ureteric stones.
Low ureteral wall thickness is associated with a greater likelihood of spontaneous passage of ureteral stones 10 mm or smaller in diameter, according to a new study.
Approved prostate cancer drug treatments including formulations and usual dosing.
